Investigating the effects of semaglutide in early Alzheimer’s disease using single‐cell transcriptomics and proteomics – rationale and design
Peter Johannsen, Marie Bentsen, Kate Attfield, Kristian Steen Frederiksen, Giovanni B Frisoni, Rose Jeppesen, Ibrahim J Malik, Lotte Bjerre Knudsen · 2025
Read Investigating the effects of semaglutide in early Alzheimer’s disease using single‐cell transcriptomics and proteomics – rationale and design by Peter Johannsen, Marie Bentsen, Kate Attfield, Kristian Steen Frederiksen, Giovanni B Frisoni, Rose Jeppesen, Ibrahim J Malik, Lotte Bjerre Knudsen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712370.txt.
Description
Peter Johannsen and seven co-authors set out the plan for a study of a diabetes drug in early Alzheimer's disease in a 2025 paper. The drug, semaglutide, acts on a gut hormone path that also touches brain swelling. Two large trials are already testing whether it slows early disease. This small study asks what it does to immune cells in blood and spinal fluid.
Twenty four people aged fifty five to seventy five with proven brain plaque will take the drug or a dummy in a blind trial. Single cell gene reads will track immune change in each arm. The authors lay out the grounds, the design, and the safety frame. Results should sharpen how the field reads the big trials.
Catalog record
| CREATOR | Peter Johannsen, Marie Bentsen, Kate Attfield, Kristian Steen Frederiksen, Giovanni B Frisoni, Rose Jeppesen, Ibrahim J Malik, Lotte Bjerre Knudsen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |